Related Experiment Video
Updated: May 13, 2026

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
Published on: December 13, 2017
Methodological issues in clinical drug development for essential tremor
Michael A Carranza1, Madeline R Snyder, Rodger J Elble
1Department of Neurology, University of South Florida, Tampa, Florida, United States of America.
Abstract:
Essential tremor (ET) is one of the most common tremor disorders in the world. Despite this, only two medications have received Level A recommendations from the American Academy of Neurology to treat it (primidone and propranolol). Even though these medications provide relief to a large group of ET patients, up to 50% of patients are non-responders. Additional medications to treat ET are needed. This review discusses some of the methodological issues that should be addressed for quality clinical drug development in ET.
More Related Videos
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
08:36The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
Published on: July 28, 2022
Related Concept Videos
Clinical Trials: Overview
Preclinical Development: Overview
Therapeutic Drug Monitoring: Affecting Factors
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Clinically Relevant Drug Product Specifications: Methods of Establishment
Clinical Trials
There are four phases in a clinical trial. A phase one...